The spectrum and types of adverse side effects to biological immune modulators: A proposal for new classification

Folia Biologica

Volumn 53, Issue 4, 2007, Pages 146-155

  Zemková, Marcela ^a,b   Jebavy L ^b,c   Kotlarova J ^b   Vlcek J ^b   Meyboom, R H B ^a,d  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Adverse side effects; Anti inflammatory therapy; Biological immune modulators; Fusion proteins; Monoclonal antibodies; Tumour therapy

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AUTOANTIBODY; BASILIXIMAB; BETA INTERFERON; CETUXIMAB; CHEMOKINE; CYTOKINE; DACLIZUMAB; EFALIZUMAB; ERYTHROPOIETIN ANTIBODY; ETANERCEPT; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5 ANTIBODY; IPILIMUMAB; MACROGOL; METHOTREXATE; OMALIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TRANSFORMING GROWTH FACTOR; UNINDEXED DRUG;

ACNE; ANAPHYLAXIS; ARTHRALGIA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BELL PALSY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFUSION; CROSS REACTION; CYTOKINE RELEASE; DEMYELINATING DISEASE; DEPRESSION; DERMATITIS; DERMATITIS HERPETIFORMIS; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DYSPHAGIA; DYSTONIA; ERYTHEMA; ERYTHROCYTE APLASIA; FACE EDEMA; FIBROSIS; FLU LIKE SYNDROME; GRAFT REJECTION; GUILLAIN BARRE SYNDROME; HEARING LOSS; HEART FAILURE; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; IMMUNOTOXICITY; INFECTION; INFLAMMATORY DISEASE; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; LICHENOID ERUPTION; LISTERIOSIS; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; NEPHRITIS; NOMENCLATURE; NONHUMAN; PANCYTOPENIA; PERNICIOUS ANEMIA; PRURITUS; PSORIASIS; RASH; RESTLESS LEGS SYNDROME; REVIEW; SARCOIDOSIS; SERUM SICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; THYROID DISEASE; TUBERCULOSIS; URTICARIA; VASCULITIS; VITILIGO; WELLS SYNDROME;

EID: 34447299908     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Abbas, A. K., Lichtman, A. H. (2005) Cellular and Molecular Immunology, 6th Ed. Philadelphia, USA: WB Saunders Company.
2. Abbas, A. K., Murphy, K. M., Sher A. (1996) Functional diversity of helper T lymphocytes. Nature 383, 787-793.
3. Abramovitz, D., Crusaix, A., Goldman, M. (1992) Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N. Engl. J. Med. 327, 736.
4. Arimura, K., Arima, N., Ohtsubo, H., Mathushita, K., Kukita, T., Ayukawa, T., Kuroki, T., Tei, C. (2004) Severe autoimmune thrombocytopenic purpura during interferon-α therapy for chronic myelogenous leukaemia. Acta Haematol. 112, 217-218.
5. Baert, F., Noman, M., Venniere, S., VanAssche, G., D'Haens, G., Carbonez, A., Rutgeerts, P. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608.
6. Bagheri, H., Fouladi, A., Barange, K., Lapeyre-Mestre, M., Payen, J. L., Montastruc, J. L., Vinel, J. P. (2004) Follow-up of adverse reactions from peg-interferon α-2b-ribavirin therapy. Pharmacotherapy 24, 1546-1553.
7. Banchereau, J., Pascual, V., Palucka, A. K. (2004) Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20, 539-550.
8. Boven, K., Knight, J., Bader, F., Rossert, J., Eckardt, K. U., Casadevall, N. (2005) Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol. Dial. Transplant. 20, 33-40.
9. Boz, C., Ozmenoglu, M., Aktoz, G., Velioglu, S., Alioglu, Z. (2004) Guillain-Barre syndrome during treatment with interferon α for hepatitis B. J. Clin. Neurosci. 11, 523-525.
10. Chamberlain A. J., Pooh, E. (2004) Cutaneous reactions to interferon and ribavirin. Intern. Med. J. 34, 519.
11. Chan, J. L., Davis-Reed, L., Kimball, A. B. (2004) Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J. Drugs Dermatol. 3, 315-318.
12. Chatenoud, L. (1993) Immunologic monitoring during OKT3 therapy. Clin. Transplant. 7, 422-430.
13. Danese, S., Fiocchi, C. (2005) Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit. Rev. Immunol. 25, 103-121.
14. Day, R. (2002) Adverse reactions to TNF-α inhibitors in rheumatoid arthritis. Lancet 359, 540-541.
15. Debandt, M., Vittecog, O., Descamps, V., Le Loet, X., Meyer, O. (2003) Anti-TNF-α-induced systemic lupus syndrome. Clin. Rheumatol. 22: 56-61.
16. Devos, S. A., Van Den Bossche, N., De Vos, M., Naeyaert, J. M. (2003) Adverse skin reactions to anti-TNF-α monoclonal antibody therapy. Dermatology 206, 388-390.
17. Doi, F., Kakizaki, S., Takagi, H., Murakami, M., Sohara, N., Outsuka, T., Abe, T., Mori, M. (2005) Long-term outcome of interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 25, 242-246.
18. Gomez-Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., Montero, M. D. (2003) Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48, 2122-2127.
19. Han, P. D., Cohen, R. D. (2004) Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 64, 1767-1777.
20. Hershberger, R. E., Starling, R. C., Eisen, H. J., Bergh, C. H., Kormos, R. L., Love, R. B., Van Bakel, A., Gordon, R. D., Popat, R., Cockey, L,, Mamelok, R. D. (2005) Daclizumab to prevent rejection after cardiac transplantation. N. Engl. J. Med. 352, 2705-2713.
21. Hoigne, R., Schlumberger, H. P., Vervloet, D., Zoppi, M. (1993) Epidemiology of allergic drug reactions. Monogr. Allergy 31, 147-170.
22. Kasahara, A., Hiraider, A., Tomita, N., Iwahashi, H., Imagawa, A., Ohguro, N., Yamamoto, S., Mita, E., Hayashi, N. (2004) Vogt-Koyanagi-Harada disease occurring during interferon α therapy for chronic hepatitis C. J. Gastroenterol. 39, 1106-1109.
23. Kassiotis, G., Kollias, G. (2001) TNF and receptors in organ-specific autoimmune disease: multi-layered functioning mirrored in animal models. J. Clin. Invest. 107, 1507-1508.
24. Kwon, H. J., Cote, T. R., Cuffe, M. S., Kramer, J. M., Braun, M. M. (2003) Case reports of heart failure after therapy with a tumour necrosis factor antagonist. Arch. Intern. Med. 138, 807-811.
25. Lee, S. J., Kavanaugh, A. (2005) Adverse reactions to biological agents: focus on autoimmune disease therapies. J. Allergy Clin. Immunol. 116, 900-905.
26. Lipsky, P. E., van der Heijde, D. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., Harriman G. R., Maini, R. N. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumour necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343, 1594-1602.
27. Menon, Y., Cucurull, E., Reisin, E., Espinoza, L. R. (2004) Interferon-α-associated sarcoidosis responsive to infliximab therapy. Am. J. Med. Sci. 328, 173-175.
28. Naisbitt, D. J., Gorgon, S. F., Pirmohamed, M., Park, B. K. (2000) Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 23, 483-507.
29. Niewold, T. B., Swedler, W. I. (2005) Systemic lupus erythematosus arising during interferon-α therapy for cryoglobulinemic vasculitis associated with hepatits C. Clin. Rheumatol. 24: 178-181.
30. Panwar, P., Iznaga-Escobar, N., Mishra, P., Srivastava, V., Sharma, R. K., Chandra, R., Mishra, A. K. (2005) Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody or egf/r3 for targeted tumour imaging and therapy. Cancer Biol. Ther. 4, 854-860.
31. Peréz-Soler R., Saltz, L. (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 23, 5235-5246.
32. Phan, C. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwarzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer L. J., Morton, K. E., Mavroukakis, S. A., Duray, P. H., Steinberg, S. M., Allison, J. P., Davis, T. A., Rosenberg, S. A. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad Sci. USA 100, 8372-8377.
33. Pichler, W. J. (2003) Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139, 683-693.
34. Rifkin, I. R., Leadbetter, E. A., Busconi, L., Viglianti, G., Marshak-Rothstein, A. (2005) Toll-like receptors, exogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204, 27-42.
35. Seckin, D., Durusoy, C., Sahin, S. (2004) Concomittant vitiligo and psoriasis in a patient treated with interferon α-2a for chronic hepatitis B infection. Pediatr Dermatol. 21, 577-579.
36. Solans, R., Bosch, J. A., Esteban, I., Vilardell, M. (2004) Systemic sclerosis developing in association with the use of interferon a therapy for chronic viral hepatitis. Clin. Exp. Rheumatol. 22, 625-628.
37. Taylor, A., Verhagen, J., Akdis, C. A., Akdis, M. (2004) T regulatory cells in allergy and health: a question of allergen specificity and balance. Int. Arch. Allergy Inmmunol. 135, 73-82.
38. Vasquez, E. M., Fabrega, A. J., Pollak, R. (1995) OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplant. Proc. 27, 873-874.
39. Vermeire, S., Noman, M., van Assche, G., Baert, F., van Steen, K., Esters, N., Joossens, S., Bossuyt, X., Rutgeerts, P. (2003) Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 125, 32-39.
40. Walker, C., Herzog, C., Rieber, P., Riethmuller, G., Muller, W., Pichler, W. L. (1989) Anti-CD4 antibody treatment of patients with rheumatoid arthritis: II. Effect of in vivo treatment on in vitro proliferative response of CD4 cells. J. Autoimmun. 2, 643-649.
41. Waugh, J., Perry, C. M. (2005) Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 19, 189-202.
42. Weber, R. W. (2004) Adverse reactions to biological modifiers. Curr. Opin. Allergy Clin. Immunol. 4, 277-283.
43. Wellington, K., Perry, C. M. (2005) Efalizumab. Am. J. Clin. Dermatol. 6, 113-120.
44. Werth, V. P., Levinson, A. I. (2001) Etanercept-induced injection site reactions: mechanistic insights from clinical finding and irmnunohistochemistry. Arch. Dermatol. 137, 953-955.